Thyroid hormone receptor alpha and thyroid hormone receptor beta (TRα and TRβ)

Thyroid hormone receptor alpha and beta are ligand-activated nuclear receptors encoded by the THRA and THRB genes, respectively. They serve as principal mediators of thyroid hormone (T3, T4) effects in mammalian tissues, functioning primarily as transcription factors to regulate gene expression in response to hormone binding. These receptors exist in multiple isoforms generated by alternative splicing, with expression patterns that vary by tissue and developmental stage. The alpha and beta subtypes have distinct though overlapping roles in metabolism, development, neural function, heart rate regulation, and cell proliferation. Dysfunction or mutation in either receptor is associated with developmental disorders such as congenital hypothyroidism and sensorineural deafness. Therapeutically, these receptors are targets for natural and synthetic thyroid hormones, as well as for investigational thyromimetics (especially selective TRβ agonists). Major safety challenges involve tissue selectivity, risk of systemic endocrine disturbance, and subtype-specific functions that complicate selective drug targeting.

Other names

TR-alpha (TRα)TR-beta (TRβ)Nuclear receptor subfamily 1, group A, member 1 (NR1A1, for TRα)Nuclear receptor subfamily 1, group A, member 2 (NR1A2, for TRβ)Thyroid hormone receptor (general)c-erbA gene products (historic context)

Agonists (e.g., thyroxine, triiodothyronine): bind to the ligand-binding domain to induce conformational change, activating transcription of thyroid-responsive genes Selective TRβ agonists: preferentially activate TRβ-driven transcription for therapeutic purposes (e.g., lipid regulation in metabolic disease) Antagonists (potentially, especially for experimental or research purposes): induce corepressor association and repress gene transcription